267 related articles for article (PubMed ID: 33755823)
1. Thiopurine Monotherapy Is Effective in Maintenance of Mild-Moderate Inflammatory Bowel Disease.
Barber GE; Hendler S; Choe M; Keyashian K; Lechner S; Limketkai BN; Limsui D
Dig Dis Sci; 2022 Apr; 67(4):1287-1294. PubMed ID: 33755823
[TBL] [Abstract][Full Text] [Related]
2. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
Balram B; Lubov J; Theoret Y; Afif W; Bitton A; Wild G; Lakatos PL; Bessissow T
Dig Dis Sci; 2021 May; 66(5):1650-1657. PubMed ID: 32591969
[TBL] [Abstract][Full Text] [Related]
3. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource.
Stournaras E; Qian W; Pappas A; Hong YY; Shawky R; ; Raine T; Parkes M;
Gut; 2021 Apr; 70(4):677-686. PubMed ID: 33004550
[TBL] [Abstract][Full Text] [Related]
4. Minimal risk of lymphoma and non-melanoma skin cancer despite long-term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India.
Ranjan MK; Kante B; Vuyyuru SK; Kumar P; Mundhra SK; Golla R; Sharma R; Sahni P; Das P; Makharia G; Kedia S; Ahuja V
J Gastroenterol Hepatol; 2022 Aug; 37(8):1544-1553. PubMed ID: 35501287
[TBL] [Abstract][Full Text] [Related]
5. Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease.
Ranjan MK; Vuyyuru SK; Kante B; Kumar P; Mundhra SK; Golla R; Sharma R; Sahni P; Das P; Makharia G; Kedia S; Ahuja V
Int J Colorectal Dis; 2022 Aug; 37(8):1817-1826. PubMed ID: 35835862
[TBL] [Abstract][Full Text] [Related]
6. Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study.
Thomsen SB; Ungaro RC; Allin KH; Elmahdi R; Poulsen G; Andersson M; Colombel JF; Jess T
Aliment Pharmacol Ther; 2022 May; 55(9):1128-1138. PubMed ID: 35080036
[TBL] [Abstract][Full Text] [Related]
7. Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease.
Choi YI; Kim TJ; Park DK; Chung JW; Kim KO; Kwon KA; Kim YJ
Int J Colorectal Dis; 2019 Oct; 34(10):1713-1721. PubMed ID: 31471699
[TBL] [Abstract][Full Text] [Related]
8. Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis.
Ranjan MK; Kumar P; Vuyyuru SK; Kante B; Mundhra SK; Golla R; Virmani S; Sharma R; Sahni P; Das P; Kalaivani M; Upadhyay AD; Makharia G; Kedia S; Ahuja V
J Crohns Colitis; 2024 Feb; 18(2):192-203. PubMed ID: 37584328
[TBL] [Abstract][Full Text] [Related]
9. Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.
Alexakis C; Saxena S; Chhaya V; Cecil E; Curcin V; Pollok R
Inflamm Bowel Dis; 2017 Apr; 23(4):672-680. PubMed ID: 28151735
[TBL] [Abstract][Full Text] [Related]
10. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
11. Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
Mak JWY; So J; Tang W; Yip TCF; Leung WK; Li M; Lo FH; Ng KM; Sze SF; Leung CM; Tsang SWC; Shan EHS; Chan KH; Lam BCY; Hui AJ; Chow WH; Chan FKL; Ng SC
Scand J Gastroenterol; 2020 Mar; 55(3):279-286. PubMed ID: 32119788
[No Abstract] [Full Text] [Related]
12. Classic drugs in the time of new drugs: real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease.
Rezazadeh Ardabili A; Jeuring S; Mujagic Z; Oostenbrug L; Romberg-Camps M; Jonkers D; van Bodegraven A; Pierik M
Aliment Pharmacol Ther; 2022 Sep; 56(6):1030-1043. PubMed ID: 35794735
[TBL] [Abstract][Full Text] [Related]
13. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.
Renna S; Cottone M; Orlando A
World J Gastroenterol; 2014 Aug; 20(29):9675-90. PubMed ID: 25110407
[TBL] [Abstract][Full Text] [Related]
14. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
[TBL] [Abstract][Full Text] [Related]
15. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C
Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308
[TBL] [Abstract][Full Text] [Related]
16. Steroid dependency and trends in prescribing for inflammatory bowel disease - a 20-year national population-based study.
Chhaya V; Saxena S; Cecil E; Subramanian V; Curcin V; Majeed A; Pollok RC
Aliment Pharmacol Ther; 2016 Sep; 44(5):482-94. PubMed ID: 27375210
[TBL] [Abstract][Full Text] [Related]
17. Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials.
Shehab M; Alrashed F; Alkazemi A; Lakatos PL; Bessissow T
Expert Rev Gastroenterol Hepatol; 2023 May; 17(5):469-477. PubMed ID: 36961082
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
Kirchgesner J; Lemaitre M; Rudnichi A; Racine A; Zureik M; Carbonnel F; Dray-Spira R
Aliment Pharmacol Ther; 2017 Jan; 45(1):37-49. PubMed ID: 27781286
[TBL] [Abstract][Full Text] [Related]
19. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.
Stocco G; Cuzzoni E; De Iudicibus S; Favretto D; Malusà N; Martelossi S; Pozzi E; Lionetti P; Ventura A; Decorti G
World J Gastroenterol; 2015 Mar; 21(12):3571-8. PubMed ID: 25834322
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients.
Thapa SD; Hadid H; Usman M; Imam W; Hassan A; Schairer J; Jafri SM; Kaur N
Dig Dis Sci; 2016 Jan; 61(1):230-7. PubMed ID: 26511478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]